6th INTERNATIONAL CONFERENCE
ACUTE MYELOID LEUKEMIA "MOLECULAR AND TRANSLATIONAL": ADVANCES IN BIOLOGY AND TREATMENT

October 29-31, 2023 - Estoril, Portugal

Chairs: Bob Löwenberg (Rotterdam), Hartmut Döhner (Ulm), Martin Tallman (Chicago)

Sunday, October 29th, 2023

09:00–09:10 **Welcome**
Bob Löwenberg (Rotterdam), Hartmut Döhner (Ulm), Martin Tallman (Chicago)

SESSION I – Clonal hematopoiesis I
Chairs: John Crispino (Memphis), Margaret Goodell (Houston)

09:10-09:25	Linking mutational processes to leukemic development	Mathijs Sanders (Rotterdam)
09:25-09:30	*Discussion*	
09:30-09:45	Evolution of clonal haematopoiesis to AML	Caroline Watson (Cambridge)
09:45-09:50	*Discussion*	
09:50-10:05	Causes and consequences of clonal haematopoiesis	George Vassiliou (Cambridge)
10:05-10:10	*Discussion*	
10:10-10:40	*Panel discussion*	
10:40-11:10	***Coffee break***	

SESSION II – Clonal hematopoiesis II
Chairs: George Vassiliou (Cambridge), Matthew Walter (St Louis)

11:10-11:25	Interrogating clonal evolution in acute myeloid leukemia	Linde Miles (Cincinnati)
11:25-11:30	*Discussion*	
11:30-11:45	Where, when and how? Characterising the properties of age-related haematopoietic clones	Paresh Vyas (Oxford)
11:45-11:50	*Discussion*	
11:50-12:05	Mechanisms of HSC clonal dominance with age	Margaret Goodell (Houston)
12:05-12:10	*Discussion*	
12:10-12:40	*Panel discussion*	

12:40-14:35 ***Lunch***

13:25-14:25 **3 Simultaneous Meet the Expert Sessions**

1. Current status of CAR-T cell therapy for AML — Saar Gill (Philadelphia)
2. New classification of AML — Robert Hasserjian (Boston)
3. New approaches for treatment of older patients — Courtney DiNardo (Houston)

13:25-14:25 **SATELLITE SYMPOSIUM**

Advances in First-Line AML Therapies: What Does it Mean for My Patients?

Chair: Hervé Dombret (Paris)

Speakers: Lars Bullinger (Berlin), Pau Montesinos (Valencia)

This medical education event is organised and funded by Daiichi Sankyo

SESSION III – Epigenetics

Chairs: Ruud Delwel (Rotterdam), Paresh Vyas (Oxford)

14:35-14:50	ERG - from stemness to myeloid leukemia	Shai Izraeli (Tel Aviv) *(virtual)*
14:50-14:55	*Discussion*	
14:55-15:10	Aberrant gene regulatory complexes and their role in AML Pathogenesis and Treatment	Brian Huntly (Cambridge)
15:10-15:15	*Discussion*	
15:15-15:30	Targeting aberrant gene control in AML	Alex Kentsis (New York)
15:30-15:35	*Discussion*	
15:35-16:05	*Panel discussion*	

16:05-16:35 ***Coffee break***

SESSION IV - Immune targeting

Chairs: Ravi Majeti (Stanford), Andrew Wei (Melbourne)

16:35-16:50	The immune landscape of AML and its correlation with immunotherapy outcomes	Sergio Rutella (Nottingham)
16:50-16:55	*Discussion*	
16:55-17:10	Immunotherapeutic targeting of AML and MDS	Saar Gill (Philadelphia)
17:10-17:15	*Discussion*	
17:15-17:30	Targeting of tumor necrosis factor receptors/CD70 in leukemia	Adrian Ochsenbein (Bern)
17:30-17:35	*Discussion*	
17:35-17:50	AML relapse after allo-HCT: hiding in plain sight	John DiPersio (St. Louis)
17:50-17:55	*Discussion*	
17:55-18:25	*Panel discussion*	

18:30-20:30 **On-Site Get-Together and Poster Walk #1 (Stand-up buffet dinner for all)**

Poster Leaders:

- *Diagnostics / NPM1 / KMT2A: Konstanze Döhner (Ulm), Hannah Uckelmann (Frankfurt)*
- *Clonal hematopoiesis and leukemia predisposition / Stem cell and cell fate / Leukemic growth, evolution and progression: John Crispino (Memphis), Ruud Delwel (Rotterdam)*

Monday, October 30th, 2023

08:00-09:00 **SATELLITE SYMPOSIUM**

Treatment choices for the mIDH1 AML patients' ineligible for intensive chemotherapy

Chair: Paresh Vyas (Oxford)

Speakers: Courtney DiNardo (Houston), Ana Pierola (Pamplona), Paresh Vyas (Oxford)

This symposium is organised and sponsored by Servier

SESSION V – Germline predisposition and clonal progression

Chairs: Coleman Lindsley (Boston), Brian Huntly (Cambridge)

09:10-09:25	Targeted protein degradation for the treatment of hematologic malignancies	Benjamin Ebert (Boston)
09:25-09:30	*Discussion*	
09:30-09:45	Insights into leukemic progression of the MPNs	John Crispino (Memphis)
09:45-09:50	*Discussion*	
09:50-10:05	Germline predisposition to myeloid malignancy	Katherine R. Calvo (Bethesda)
10:05-10:10	*Discussion*	
10:10-10:40	*Panel discussion*	

10:40-11:10 ***Coffee break***

SESSION VI - Therapeutic targeting I

Chairs: Eytan Stein (New York), Andrew Wei (Melbourne)

11:10-11:25	Therapeutic targeting of BCL-2	Courtney DiNardo (Houston)
11:25-11:30	*Discussion*	
11:30-11:45	BCL-2 inhibition: resistance and combinations	Marina Konopleva (New York)
11:45-11:50	*Discussion*	
11:50-12:20	*Panel discussion*	

12:20-14:15 ***Lunch***

13:05-14:05 **3 Simultaneous Meet the Expert Sessions**

1. Germline predisposition — Katherine Calvo (Bethesda)
2. How to deal with clonal hemopoiesis in a clinical setting — Coleman Lindsley (Boston)
3. Targeted therapy for AML — Eunice Wang (Buffalo)

SESSION VII - Therapeutic targeting II
Chairs: Benjamin Ebert (Boston), Marina Konopleva (New York)

14:15-14:30	Harnessing functional assays for precision medicine in AML	Raphael Itzykson (Paris)
14:30-14:35	*Discussion*	
14:35-14:50	Single-cell technologies to dissect cellular landscapes in acute myeloid leukemia	Simon Haas (Berlin)
14:50-14:55	*Discussion*	
14:55-15:10	Functional single cell assessments in leukemia	Philipp Staber (Vienna)
15:10-15:15	*Discussion*	
15:15-15:45	*Panel discussion*	
15:45-16:15	***Coffee Break***	

SESSION VIII - Therapeutic targeting III
Chairs: Hervé Dombret (Paris), John DiPersio (St. Louis)

16:15-16:30	Interfering with hijacked enhancer in AML	Ruud Delwel (Rotterdam)
16:30-16:35	*Discussion*	
16:35-16:50	Therapeutic targeting of splicing factors	Matthew Walter (St. Louis)
16:50-16:55	*Discussion*	
16:55-17:10	Therapeutic targeting of NPM1	Hannah Uckelmann (Frankfurt)
17:10-17:15	*Discussion*	
17:15-17:30	Therapeutic targeting of Menin	Eytan Stein (New York)
17:30-17:35	*Discussion*	
17:35-18:05	*Panel discussion*	

18:05-19:35 **Poster Walk #2**
Poster Leaders:
- *Minimal Residual Disease / Therapeutic resistance: Hervé Dombret (Paris), Peter Valk (Rotterdam)*
- *Immunobiology / Therapeutic targeting: Lars Bullinger (Berlin), Mike Dennis (Manchester)*

Tuesday, October 31st, 2023

SESSION IX – MDS / Secondary leukemia
Chairs: Raphaël Itzykson (Paris), Martin Tallman (Chicago)

08:15-08:30	The biologic heterogeneity of secondary AML	Robert Hasserjian (Boston)
08:30-08:35	*Discussion*	
08:35-08:50	Molecular mechanisms driving secondary AML transformation	Coleman Lindsley (Boston)

08:50-08:55	*Discussion*	
08:55-09:10	MCL1 and related pro-survival targets in AML	Andrew Wei (Melbourne)
09:10-09:15	*Discussion*	
09:15-09:45	*Panel discussion*	

SESSION X - Therapeutic targeting IV
Chairs: Hartmut Döhner (Ulm), Bob Löwenberg (Rotterdam)

09:45-10:00	NGS-based molecular MRD monitoring in AML	Peter Valk (Rotterdam)
10:00-10:05	*Discussion*	
10:05-10:20	Surface Antigen Targeting in AML: CD47 and Beyond	Ravi Majeti (Stanford)
10:20-10:25	*Discussion*	
10:25-10:40	Therapeutic targeting of FLT3	Alexander Perl (Philadelphia)
10:40-10:45	*Discussion*	
10:45-11:00	Therapeutic targeting of IDH1/IDH2	Eunice Wang (Buffalo)
11:00-11:05	*Discussion*	
11:05-11:35	*Panel discussion*	
11:35-11:45	***Closing remarks***	

MEETING CLOSURE